Abstract
Hepatitis C virus (HCV) remains a public health problem of global importance, even in the era of potent directly-acting antiviral drugs. In this chapter, I discuss immune responses to acute and chronic HCV infection. The outcome of HCV infection is influenced by viral strategies that limit or delay the initiation of innate antiviral responses. This delay may enable HCV to establish widespread infection long before the host mounts effective T and B cell responses. HCV’s genetic agility, resulting from its high rate of replication and its error prone replication mechanism, enables it to evade immune recognition. Adaptive immune responses fail to keep up with changing viral epitopes. Neutralizing antibody epitopes may be hidden by decoy structures, glycans, and lipoproteins. T cell responses fail due to changing epitope sequences and due to exhaustion, a phenomenon that may have evolved to limit immune-mediated pathology. Despite these difficulties, innate and adaptive immune mechanisms do impact HCV replication. Immune-mediated clearance of infection is possible, occurring in 20-50% of people who contract the disease. New developments raise hopes for effective immunological interventions to prevent or treat HCV infection.
Keywords: Hepatitis C virus, immune response, innate immunity, T cell exhaustion, interferon lambda, neutralizing antibodies.
Current Drug Targets
Title:Innate and Adaptive Immune Responses in Chronic HCV Infection
Volume: 18 Issue: 7
Author(s): Lynn B. Dustin*
Affiliation:
- University of Oxford, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, Kennedy Institute of Rheumatology, Peter Medawar Building for Pathogen Research, South Parks Road, Oxford OX1 3SY,United Kingdom
Keywords: Hepatitis C virus, immune response, innate immunity, T cell exhaustion, interferon lambda, neutralizing antibodies.
Abstract: Hepatitis C virus (HCV) remains a public health problem of global importance, even in the era of potent directly-acting antiviral drugs. In this chapter, I discuss immune responses to acute and chronic HCV infection. The outcome of HCV infection is influenced by viral strategies that limit or delay the initiation of innate antiviral responses. This delay may enable HCV to establish widespread infection long before the host mounts effective T and B cell responses. HCV’s genetic agility, resulting from its high rate of replication and its error prone replication mechanism, enables it to evade immune recognition. Adaptive immune responses fail to keep up with changing viral epitopes. Neutralizing antibody epitopes may be hidden by decoy structures, glycans, and lipoproteins. T cell responses fail due to changing epitope sequences and due to exhaustion, a phenomenon that may have evolved to limit immune-mediated pathology. Despite these difficulties, innate and adaptive immune mechanisms do impact HCV replication. Immune-mediated clearance of infection is possible, occurring in 20-50% of people who contract the disease. New developments raise hopes for effective immunological interventions to prevent or treat HCV infection.
Export Options
About this article
Cite this article as:
Dustin B. Lynn*, Innate and Adaptive Immune Responses in Chronic HCV Infection, Current Drug Targets 2017; 18 (7) . https://dx.doi.org/10.2174/1389450116666150825110532
DOI https://dx.doi.org/10.2174/1389450116666150825110532 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phosphodiesterase Inhibitors as Potential Cognition Enhancing Agents
Current Topics in Medicinal Chemistry Nasal Polyposis: An Overview of Differential Diagnosis and Treatment
Recent Patents on Inflammation & Allergy Drug Discovery Oncogenic Fusion Tyrosine Kinases as Molecular Targets for Anti-Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Peptides Derived from Platelet Non-integrin Collagen-receptors or Types I and III Collagen Inhibit Collagen-Platelet Interaction
Cardiovascular & Hematological Disorders-Drug Targets The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review
Current Drug Safety Impaired Clearance of Neutrophils Extracellular Trap (NET) May Induce Detrimental Tissular Effect
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Subject Index To Volume 2
Current Rheumatology Reviews Recent Advances in Pegylated Interferon Antiviral Therapy of Chronic Hepatitis C
Anti-Infective Agents in Medicinal Chemistry Characterization and Management of Cutaneous Side Effects Related to the Immunosuppressive Treatment in Solid Organ Recipients
Current Drug Targets Acute Severe Arterial Hypertension: Therapeutic Options
Current Drug Targets Monocyte Adhesion in Atherosclerosis: A Biomechanical Approach
Vascular Disease Prevention (Discontinued) The Role of Endothelin System in Cardiovascular Disease and the Potential Therapeutic Perspectives of its Inhibition
Current Topics in Medicinal Chemistry Single Photon Emission Tomography in the Diagnostic Assessment of Cardiac and Vascular Infectious Diseases
Current Radiopharmaceuticals TAP-Independent MHC Class I Presentation
Current Immunology Reviews (Discontinued) Acute Ischemic Cerebrovascular Events on Antiplatelet Therapy: What is the Optimal Prevention Strategy?
Current Pharmaceutical Design The Role of C-Reactive Protein in Atherosclerotic Cardiovascular Disease: An Overview
Current Vascular Pharmacology Antibody-Based Therapies in Systemic Lupus Erythematosus
Mini-Reviews in Medicinal Chemistry The Risk of Progressive Multifocal Leukoencephalopathy Under Biological Agents Used in the Treatment of Chronic Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) The Treatment of Chronic Hepatitis C not Responding to Interferon
Current Pharmaceutical Design Genetic Studies of Type 2 Diabetes in South Asians: A Systematic Overview
Current Diabetes Reviews